International Stem Cell Corporation ISCO

Company Overview

International Stem Cell Corporation (ISCO) is a biotechnology company focused on regenerative medicine, stem cell research, and cell-based therapeutic development. The company became known for its work in human parthenogenetic stem cells (hpSCs), a stem cell platform derived from unfertilized human eggs that was designed to address certain ethical and immunological limitations associated with embryonic stem cells. ISCO has operated primarily within the biotechnology, regenerative medicine, and biomedical research industries, with activities spanning therapeutic research, laboratory products, and contract research support.

Historically, the company generated revenue through a combination of research products, cell culture media, stem cell technologies, and therapeutic development programs. ISCO also developed skin-care and biomedical products through affiliated business units. The company’s strategic positioning centered on proprietary stem cell technologies and intellectual property related to parthenogenetic stem cells, which it promoted as a potentially scalable source for regenerative therapies. Public disclosures in SEC filings and historical investor materials indicate that ISCO evolved from a research-focused stem cell developer into a broader regenerative medicine platform company with commercial laboratory product operations supporting ongoing research activities.